Concepedia

Author

A.-R. Hanauske

Technical University of Munich

Also Known As

A Hanauske, A R Hanauske, A-R Hanauske, A-R. Hanauske, A. -R. Hanauske, A. Hanauske, A. R. Hanauske, A.-R. Hanauske, A.R. Hanauske, AR Hanauske

67

Publications

868

Citations

15

H-Index

32

Concepts

All Affiliations

Technical University of MunichKlinikum rechts der IsarRotterdam University of Applied SciencesHeidelberg UniversityVrije Universiteit Amsterdam
AH

About

A.-R. Hanauske is an author at Technical University of Munich specializing in medicine, oncology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

17

641

2

Cell Biology

5

5

200

3

Biochemistry

1

1

20

4

Biomolecular Engineering

1

1

16

5

Immunology

1

1

36

A.-R. Hanauske

×

19

Publications

754

Citations

15

H-Index

YearCitations

Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck

Patrick Schöffski, G. Catimel, A.S.T. Planting,

Annals of Oncology

1999

104

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

Simone Steinbild, K. Mross, Annette Frost,

British Journal of Cancer

2007

101

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells

H. Depenbrock, Robert Peter, G T Faircloth,

British Journal of Cancer

1998

83

Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

Chris Twelves, Klaas Hoekman, A. Bowman,

European Journal of Cancer

2003

83

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation

Ian Judson, T. Cerny, Ron Epelbaum,

Annals of Oncology

1997

54

Preclinical activity of trans-indazolium [tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells

H. Depenbrock, S. Schmelcher, Robert Peter,

European Journal of Cancer

1997

53

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study

Malcolm Ranson, Martin Reck, Alan Anthoney,

Annals of Oncology

2010

39

Effects of cytokines on in vitro colony formation of primary human tumour specimens

M. Joraschkewitz, H. Depenbrock, Mathias Freund,

European Journal of Cancer and Clinical Oncology

1990

36

Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion

R. Thödtmann, Andreas Hüttmann, W.E. Berdel,

Investigational New Drugs

1998

33

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC—ECSG phase II clinical study

Teresa Gamucci, R Paridaens, Bernhard Heinrich,

Annals of Oncology

2000

26

Page 1